Resultados de Búsqueda
It is advisable to change to a treatment with an oral anticoagulant if there are no contraindications and there are no problems with access or availability for the drug, in patients with mild ...
Evidencias COVID-19
Centro Cochrane Iberoamericano
A consensus document establishes the main guidelines regarding thromboembolic disease management in the context of the COVID-19 pandemic
ver más ... 2020If patients have been taking antithrombotic agents due to a prior known thromboembolic disease, they should continue their antithrombotic treatment as recommended, as the risk of severe COVID-19 due ...
Evidencias COVID-19
Centro Cochrane Iberoamericano
A consensus document establishes the main guidelines regarding thromboembolic disease management in the context of the COVID-19 pandemic
ver más ... 2020It should be recommended to increase mobility in non-hospitalized patients with mild COVID-19 and risk of VTE.
Evidencias COVID-19
Centro Cochrane Iberoamericano
In non-hospitalized patients with mild COVID-19, increased mobility should be recommended. Although indiscriminate use of drug therapy for VTE prophylaxis should not be pursued, it is reasonable to conduct a risk assessment of VTE and bleeding. Pharmacological prophylaxis may be indicated after having individually assessed the risk in patients with a high risk of VTE without a high risk of bleeding.
ver más ... 2020Non-pharmacological interventions have reduced the number of reproduction (Rt) to 1.43 in the group of countries considered, which corresponds to a reduction of 64% with respect to the value prior to ...
Evidencias COVID-19
Centro Cochrane Iberoamericano
In Spain, a model developed by Imperial College London estimates that 15.0% of the population (7.0 million people; ICr95% 1.8 to 19) would be infected as of March 28, 2020. The model estimates that non-pharmacological interventions applied to curb the epidemic would have prevented 16,000 deaths (ICr95% 5,400 to 35,000). Across the 11 European countries evaluated, they would have avoided 59,000 deaths (ICr95% 21,000 to 120,000). Non-pharmacological interventions have had a substantial impact on ...
ver más ... 2020The results of clinical trials that have evaluated the efficacy of hydroxychloroquine in the treatment of COVID-19 have shown inconclusive results, which must be interpreted with caution due to the ...
Evidencias COVID-19
Centro Cochrane Iberoamericano
According to the results of an open, non-randomized clinical trial, hydroxychloroquine (at a dose of 600 mg per day) reduces the viral load of the SARS-CoV-2 coronavirus to the nasopharynx in patients with COVID-19 from the third day of treatment, with a more evident effect in patients receiving the treatment in combination with azithromycin (500 mg on the first day and 250 mg on the following four days). This study, however, has a very small sample, and has not yet described the clinical ...
ver más ... 2020